Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...

There may be substantial upsides to this potential from new indications in e.g. urticaria. Under the agreement ... and other allergens as well as idiopathic or exercise induced anaphylaxis in adults ...

FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestonesZevra received ...

Management of urticaria de pends on its cause. Aggravating factors should be identified from the history, and triggering stimuli for physical urticaria avoided. Simple cooling lotions, as 0.5% to ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

What is juvenile idiopathic arthritis? Juvenile idiopathic arthritis (JIA) is a form of arthritis in children. Arthritis causes joint swelling (inflammation) and joint stiffness. JIA is arthritis that ...

2328.TW Pan-International Industrial Corp.